Kennedy sets HELP agenda, FDA prepares for reforms and user fee debate

27 November 2006

US Senator Edward Kennedy (Democrat, Massachusetts), has outlined the agenda for the Senate Health, Education, Labor and Pensions Committee on drug safety and Food and Drug Administration reform. Over the coming year, the US Congress is expected to debate the renewal of the 1992 Prescription Drug User Fee Act, originally proposed by Democrats and renewed by Republicans in 1997.

Sen Kennedy told the Massachusetts-based newspaper, the Boston Globe, that "science has, too often, had to take a back seat at the very agency which should be setting the standard for objectivity and integrity." He added: "there is growing evidence that the dedicated professionals at the FDA have been pressured to trim their scientific views to the prevailing political winds." To overcome this, the Massachusetts Senator proposed to hold oversight hearings into the FDA in early 2007.

"Medicare for all"...by installments

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight